Expertise in
4
conditions

Alastair P. Greystoke

Freeman Road, 
Newcastle Upon Tyne, ENG, GB 
Expertise in
4
conditions
Freeman Road, 
Newcastle Upon Tyne, ENG, GB 

Overview

Alastair Greystoke practices practicing medicine in Newcastle Upon Tyne, United Kingdom.

Mr. Greystoke is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Small Cell Lung Cancer (SCLC).

He is actively involved in clinical research, co-authoring 112 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Freeman Road, Newcastle Upon Tyne, ENG NE77DN, United Kingdom
Other Locations
Manchester, ENG M133PL, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: AZD4547, Vistusertib, Palbociclib, Crizotinib, Selumetinib, Docetaxel, AZD5363, Osimertinib, Durvalumab, Sitravatinib, AZD6738
Study Phase: Phase 2
FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours
FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2026
Intervention Type: Drug
Study Phase: Phase 1
REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer
REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Cis/carboplatin, Etoposide
Study Phase: Phase 2
A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in Combination With the Oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort).
A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in Combination With the Oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort).
Enrollment Status: Completed
Publish Date: October 07, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

112 Total Publications

The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion.
The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 25, 2026

Frequently Asked Questions about Alastair P. Greystoke

Is Alastair P. Greystoke a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Alastair P. Greystoke is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alastair P. Greystoke participate in research or clinical trials?

Yes. Alastair P. Greystoke has published 112 articles and abstracts on conditions like Lung Cancer. You can view a list of Alastair P. Greystoke's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Greystoke's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile